Pharmosa Biopharm Inc. (TPEX: 6875)
Health Care · Biotechnology · TW
NT$32.20
-2.57% today · -34.7% 1Y
Pharmosa Biopharm Inc. (TPEX: 6875) operates in the Biotechnology industry within the Health Care sector. The company is valued at $130.63M and employs 15 people.
Over the last twelve months the share price has lost 34.7%, trading between 31.00 and 65.00.
Tweenvest scores Pharmosa Biopharm Inc. across four factors: quality 46/100, value 37/100. Its strongest factor is quality.
6875 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $130.63M
- Revenue (TTM)
- $1.68M
- P/E
- —
- EPS
- -2.71
- Dividend yield
- —
- Beta (5Y)
- 0.19
- 52-week high
- NT$65.00
- 52-week low
- NT$31.00
- Avg volume (3M)
- —
- Shares outstanding
- 129.18M
- Employees
- 15
- Next earnings
- —
About Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology firm based in Taiwan, specializes in the development of pharmaceutical products. Its current pipeline includes two key candidates: L606 and L608. L606 is an investigational inhalation/device combination therapy designed to treat both pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. Similarly, L608 is another inhalation-based therapy, paired with a device, aimed at addressing pulmonary vascular disease. The company, which was established in 2000, originally operated under the name Pharmosa Limited before adopting its current name, Pharmosa Biopharm Inc., in October 2016. Its main offices are located in Taipei City, Taiwan.
- Founded
- 2000
- Listed since
- Feb 22, 2022
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.